0.9% SODIUM CHLORIDE INJECTION USP 0.9 %
SODIUM CHLORIDE : 0.9 % · DIN 01924303 · B. BRAUN MEDICAL INC
Health Canada status: MARKETED
What is 0.9% SODIUM CHLORIDE INJECTION USP?
0.9% SODIUM CHLORIDE INJECTION USP 0.9 % contains SODIUM CHLORIDE : 0.9 %. It is listed in the Health Canada Drug Product Database under DIN 01924303, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 25-Apr-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is 0.9% SODIUM CHLORIDE INJECTION USP used for?
Source of electrolytes and water for hydration; pharmaceutic aid/diluent for drug additives; extracellular fluid replacement; treatment of metabolic alkalosis; priming solution for hemodialysis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01924303 |
|---|---|
| Brand name | 0.9% SODIUM CHLORIDE INJECTION USP |
| Generic / active ingredient | SODIUM CHLORIDE : 0.9 % |
| Manufacturer | B. BRAUN MEDICAL INC |
| Strength | 0.9 % |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA03 SODIUM CHLORIDE |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Apr-1998 |
| Original market date | 1992-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01924303 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1924303 |
| Brand name | 0.9% SODIUM CHLORIDE INJECTION USP |
| Active ingredient / INN | SODIUM CHLORIDE : 0.9 % |
| ATC code | B05XA03 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05 |
| AHFS class | 40:12.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | B. BRAUN MEDICAL INC |
How is it administered?
For intravenous use only. Dosage depends on age, weight, and clinical condition. Average adult daily requirements met by 1 liter. Inspect for particulates before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (25°C); brief exposure up to 40°C permitted. Avoid excessive heat. Protect from freezing.
How is it supplied?
EXCEL Containers: 1000 mL (12 per case), 500 mL (24 per case), and 250 mL (24 per case).
Which pack is which?
| Strength on the label | 0.9 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | EXCEL Containers: 1000 mL (12 per case), 500 mL (24 per case), and 250 mL (24 per case). |
| Storage | Store at room temperature (25°C); brief exposure up to 40°C permitted. Avoid excessive heat. Protect from freezing. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Contraindicated where administration of sodium or chloride could be clinically detrimental; hypersensitivity to the drug, any ingredient, or container component.
Warnings and precautions
Risk of fluid/solute overload, pulmonary edema, and hypernatremia. Use with care in patients with CHF, renal insufficiency, hypervolemia, or sodium retention.
Is SODIUM CHLORIDE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B05XA03 SODIUM CHLORIDE. 11 of 37 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 0.45% SODIUM CHLORIDE INJECTION USP | 4.5 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01927949 |
| 0.9% SODIUM CHLORIDE INJECTION | 500ML | Solution | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02395150 |
| 0.9% SODIUM CHLORIDE INJECTION, USP | 900 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060208 |
| 20% SODIUM CHLORIDE INJECTION, BP | 20 % | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02514184 |
| 5% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01928007 |
| SODIUM CHLORIDE 0.45% INJ | 450 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 00060186 |
| SODIUM CHLORIDE 3% INJ | 3 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060232 |
| SODIUM CHLORIDE INJECTION USP | 9 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00037842 |
| SODIUM CHLORIDE INJECTION USP | 9 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00037796 |
| SODIUM CHLORIDE INJECTION, USP | 234 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02139510 |
Who else supplies SODIUM CHLORIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SODIUM CHLORIDE appears in 5432 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.